Bioxodes
PrivateLast Round
Series B
Dec 10, 2025
Total Funding Raised
$25.25M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Bioxodes is a clinical-stage biopharmaceutical company that develops therapies to treat thrombotic and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Bioxodes Comparables
Compare Bioxodes with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Op2Lysis | 88% | |
| Cayuga Biotech | 76% | |
| Lys Therapeutics | 71% |
Bioxodes Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Dec 10, 2025 | ||||
| Series A Extension | Feb 12, 2025 | ||||
| Grant | Nov 21, 2023 | ||||
| Series A | Nov 21, 2023 | ||||
| Seed | Nov 26, 2013 | ||||
Grant | Nov 1, 2013 |
Bioxodes Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Federal Holding and Investment Company | Series A Extension |
| Newton Biocapital | Series B |
| Life Sciences Research Partners | Series B, Seed, Series A Extension, Series A |
| European Regional Development Fund | Grant, Seed |
| Financière Spin-off Luxembourgeoise | Series B, Seed, Series A Extension, Series A |
| Walloon Region (Belgium) | Seed, Series A |
| Sambrinvest | Series B, Seed, Series A Extension, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2026
Monthly visitors increased 64% MoM, reaching 2.1K.
- Apr 17, 2026
BIOX-101 for ICH is in dialogue with regulators for pivotal trial design.
Recent news
Latest coverage and updates
- attends_eventSep 24, 2026
Bioxodes will attend event 18th World Stroke Congress on Oct 21st '26.
Bioxodes Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Bioxodes's valuation, stock price, and market status.
Is Bioxodes a public or private company?
Bioxodes is a private company.
What is the current stock price of Bioxodes?
Bioxodes is a private company with no public stock price. No recent secondary market data is available.
How much is Bioxodes worth (valuation)?
Valuation information for Bioxodes is not publicly available.
Can I buy Bioxodes stock?
Bioxodes shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Bioxodes's last funding round?
Bioxodes's most recent funding round was Series A Extension on December 10, 2025.
Who are the main investors in Bioxodes?
Key investors in Bioxodes include Newton Biocapital.
Will Bioxodes IPO soon?
No public IPO plans have been announced for Bioxodes.
How can I track Bioxodes secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Bioxodes's secondary market activity and sign up for updates.